Roche to Invest $2 Billion in North Carolina Facility
Roche's Genentech will double its North Carolina investment to $2 billion, expanding a facility in Holly Springs to produce obesity treatments and create 2,000 jobs.
Insights:
Roche's Genentech announced on January 20, 2026, that it will more than double its initial investment in a biomanufacturing facility in North Carolina to approximately $2 billion. This significant increase from the previous commitment of over $700 million, made in May 2025, underscores the company's strategic focus on expanding its manufacturing capabilities in the United States.
